Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;108:2393-2399
Published online before print October 13, 2003, doi: 10.1161/01.CIR.0000093187.42015.6C
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/19/2393    most recent
01.CIR.0000093187.42015.6Cv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yue, T.-l.
Right arrow Articles by Ohlstein, E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yue, T.-l.
Right arrow Articles by Ohlstein, E. H.
Related Collections
Right arrow Acute myocardial infarction

(Circulation. 2003;108:2393.)
© 2003 American Heart Association, Inc.


Basic Science Reports

Activation of Peroxisome Proliferator–Activated Receptor-{alpha} Protects the Heart From Ischemia/Reperfusion Injury

Tian-li Yue, PhD; Weike Bao, MD; Beat M. Jucker, PhD; Juan-li Gu, MD; Anne M. Romanic, PhD; Peter J. Brown, PhD; Jianqi Cui, PhD; Douglas T. Thudium, MS; Rogely Boyce, PhD; Cynthia L. Burns-Kurtis, MS; Rosanna C. Mirabile, BS; Karpagam Aravindhan, MS; Eliot H. Ohlstein, PhD

From GlaxoSmithKline Pharmaceuticals, King of Prussia, Pa.

Correspondence to Tian-li Yue, PhD, Cardiovascular Pharmacology, GSK, 709 Swedeland Rd, King of Prussia, PA 19406. E-mail tian-li_yue{at}gsk.com

Received August 28, 2002; de novo received April 9, 2003; revision received July 9, 2003; accepted July 11, 2003.

Background— Peroxisome proliferator–activated receptor-{alpha} (PPAR-{alpha}) is expressed in the heart and regulates genes involved in myocardial fatty acid oxidation (FAO). The role of PPAR-{alpha} in acute ischemia/reperfusion myocardial injury remains unclear.

Methods and Results— The coronary arteries of male mice were ligated for 30 minutes. After reperfusion for 24 hours, ischemic and infarct sizes were determined. A highly selective and potent PPAR-{alpha} agonist, GW7647, was administered by mouth for 2 days, and the third dose was given 1 hour before ischemia. GW7647 at 1 and 3 mg · kg-1 · d-1 reduced infarct size by 28% and 35%, respectively (P<0.01), and myocardial contractile dysfunction was also improved. Cardioprotection by GW7647 was completely abolished in PPAR-{alpha}–null mice. Ischemia/reperfusion downregulated mRNA expression of cardiac PPAR-{alpha} and FAO enzyme genes, decreased myocardial FAO enzyme activity and in vivo cardiac fat oxidation, and increased serum levels of free fatty acids. All of these changes were reversed by GW7647. Moreover, GW7647 attenuated ischemia/reperfusion-induced release of multiple proinflammatory cytokines and inhibited neutrophil accumulation and myocardial expression of matrix metalloproteinases-9 and -2. Furthermore, GW7647 inhibited nuclear factor-{kappa}B activation in the heart, accompanied by enhanced levels of inhibitor-{kappa}B{alpha}.

Conclusions— Activation of PPAR-{alpha} protected the heart from reperfusion injury. This cardioprotection might be mediated through metabolic and antiinflammatory mechanisms. This novel effect of the PPAR-{alpha} agonist could provide an added benefit to patients treated with PPAR-{alpha} activators for dyslipidemia.


Key Words: receptors • ischemia • reperfusion • myocardial infarction




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
J. R. Ussher and G. D. Lopaschuk
The malonyl CoA axis as a potential target for treating ischaemic heart disease
Cardiovasc Res, July 15, 2008; 79(2): 259 - 268.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T.-L. Yue, S. S. Nerurkar, W. Bao, B. M. Jucker, L. Sarov-Blat, K. Steplewski, E. H. Ohlstein, and R. N. Willette
In Vivo Activation of Peroxisome Proliferator-Activated Receptor-{delta} Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 466 - 474.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
B. M. Jucker, D. Yang, W. M. Casey, A. R. Olzinski, C. Williams, S. C. Lenhard, J. J. Legos, C. T. Hawk, S. K. Sarkar, and S. J. Newsholme
Selective PPAR{delta} agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study
Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1256 - E1264.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T.-A. S. Duhaney, L. Cui, M. K. Rude, N. K. Lebrasseur, S. Ngoy, D. S. De Silva, D. A. Siwik, R. Liao, and F. Sam
Peroxisome Proliferator-Activated Receptor {alpha}-Independent Actions of Fenofibrate Exacerbates Left Ventricular Dilation and Fibrosis in Chronic Pressure Overload
Hypertension, May 1, 2007; 49(5): 1084 - 1094.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. N. Finck
The PPAR regulatory system in cardiac physiology and disease
Cardiovasc Res, January 15, 2007; 73(2): 269 - 277.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
V. Y. Ng, C. Morisseau, J. R. Falck, B. D. Hammock, and D. L. Kroetz
Inhibition of Smooth Muscle Proliferation by Urea-Based Alkanoic Acids via Peroxisome Proliferator-Activated Receptor {alpha}-Dependent Repression of Cyclin D1
Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2462 - 2468.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. J. Gilde, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
G. J. van der Vusse and M. van Bilsen
Free Fatty Acids and Postischemic Myocardial Function.
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 231 - 235.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. G. Neilan, G. A. Doherty, G. Chen, C. Deflandre, H. McAllister, R. K. Butler, S. E. McClelland, E. Kay, L. R. Ballou, and D. J. Fitzgerald
Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin
Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H532 - H536.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Asai, K. Okumura, R. Takahashi, H. Matsui, Y. Numaguchi, H. Murakami, R. Murakami, and T. Murohara
Combined therapy with PPAR{alpha} agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency
Cardiovasc Res, June 1, 2006; 70(3): 566 - 577.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Yamaguchi, S. Matsushita, K. Motojima, F. Hirose, and T. Osumi
MLDP, a Novel PAT Family Protein Localized to Lipid Droplets and Enriched in the Heart, Is Regulated by Peroxisome Proliferator-activated Receptor {alpha}
J. Biol. Chem., May 19, 2006; 281(20): 14232 - 14240.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T. G. Neilan, D. S. Jassal, M. F. Scully, G. Chen, C. Deflandre, H. McAllister, E. Kay, S. C. Austin, E. F. Halpern, J. H. Harmey, et al.
Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression
Eur. Heart J., May 2, 2006; 27(10): 1251 - 1256.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Zambon, P. Gervois, P. Pauletto, J.-C. Fruchart, and B. Staels
Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators: Clinical and Experimental Evidence
Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 977 - 986.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Xu, L. Lu, C. Greyson, M. Rizeq, K. Nunley, B. Wyatt, M. R. Bristow, C. S. Long, and G. G. Schwartz
The PPAR-{alpha} activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1798 - H1807.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. Sambandam, D. Morabito, C. Wagg, B. N. Finck, D. P. Kelly, and G. D. Lopaschuk
Chronic activation of PPAR{alpha} is detrimental to cardiac recovery after ischemia
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H87 - H95.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
Z Yuan, Y Liu, Y Liu, J Zhang, C Kishimoto, Y Wang, A Ma, and Z Liu
Cardioprotective effects of peroxisome proliferator activated receptor {gamma} activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor {kappa}B blockade
Heart, September 1, 2005; 91(9): 1203 - 1208.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. J. Crozier, T. C. Vary, S. R. Kimball, and L. S. Jefferson
Cellular energy status modulates translational control mechanisms in ischemic-reperfused rat hearts
Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1242 - H1250.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
O. Dewald, S. Sharma, J. Adrogue, R. Salazar, G. D. Duerr, J. D. Crapo, M. L. Entman, and H. Taegtmeyer
Downregulation of Peroxisome Proliferator-Activated Receptor-{alpha} Gene Expression in a Mouse Model of Ischemic Cardiomyopathy Is Dependent on Reactive Oxygen Species and Prevents Lipotoxicity
Circulation, July 19, 2005; 112(3): 407 - 415.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
N. Marx, H. Duez, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells
Circ. Res., May 14, 2004; 94(9): 1168 - 1178.
[Abstract] [Full Text] [PDF]